VINCAMINE HYDROCHLORIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C21H26N2O3.ClH
Molecular Weight	390.904
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.[H][C@]12N3CCC[C@@]1(CC)C[C@@](O)(N4C5=CC=CC=C5C(CC3)=C24)C(=O)OC

InChI

InChIKey=YGKAKNJJNTVSKB-YAFGAGFVSA-N

InChI=1S/C21H26N2O3.ClH/c1-3-20-10-6-11-22-12-9-15-14-7-4-5-8-16(14)23(17(15)18(20)22)21(25,13-20)19(24)26-2;/h4-5,7-8,18,25H,3,6,9-13H2,1-2H3;1H/t18-,20+,21+;/m1./s1

HIDE SMILES / InChI

Description
Sources: http://www.biofarm.ro/Vincamine-SR-s29-p178-en.htm | https://nootopics.com/vincamine-dosage/ | http://www.hnkeyuan.com/anti_cancer/Vincamine.html

Vincamine is the major alkaloid of Vinca minor. Although vincamine has been used therapeutically for almost three decades, the exact mechanisms of action and its effects are still unknown. Vincamine is a peripheral vasodilator that increases blood flow to the brain. Vincamine is beneficial to the nervous system's cells feeding and protecting processes and is utilized as an adjuvant in case of cerebrovascular insufficiency, age-related psycho-behavioral disorders, post concussion syndrome in head trauma, in case of post-stroke sequels. Vincamine may be used as a dietary nootropic supplement.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Sodium channel alpha subunits; brain (Types I, II, III) 28 Target ID: CHEMBL2095171 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8957220	Blocker 537		1.9 µM [IC50]
vasodilation 8 Target ID: GO:0042311 Sources: https://elitenootropics.com/vincamine-natural-brain-nootropic/ \| https://www.covex.com/products/api/vincamine/ \| https://nootriment.com/vincamine/	Activator 1430

Conditions

Condition	Modality	Targets	Highest Phase	Product
Cerebrovascular insufficiency 15 Sources: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X1975000100003 https://www.ncbi.nlm.nih.gov/pubmed/351463 https://www.ncbi.nlm.nih.gov/pubmed/6500776 https://www.ncbi.nlm.nih.gov/pubmed/6389380 https://www.ncbi.nlm.nih.gov/pubmed/3949275	Primary		Approved 8429	Oxybral Approved Use Oxybral (Vincamine) is indicated to normalize and adapt the cerebral blood flow according to the metabolic needs and in turn improves, regulates and maintains all the brain functions, reflecting better performance physically and intellectually. Vincamine is beneficial to the nervous system's cells feeding and protecting processes and is utilized as an adjuvant in case of cerebrovascular insufficiency, age related psycho-behavioral disorders, post concussion syndrome in head trauma, in case of post-stroke sequels.

PubMed

Title	Date	PubMed
Screening for new compounds with antiherpes activity.	1984 Oct	6517562
Lipophilicity of vinpocetine and related compounds characterized by reversed-phase thin-layer chromatography.	2003 May 9	12830921
Catharanthus roseus flower extract has wound-healing activity in Sprague Dawley rats.	2006 Dec 21	17184528
Development and application of an automated solution stability assay for drug discovery.	2006 Feb	16234336
Effect of vinpocetine on retrograde axoplasmic transport.	2007	17319607
Synthesis of (+/-)-3H-epivincamine via a Rh(II)-triggered cyclization/cycloaddition cascade.	2007 Aug 16	17658832
Impaired cognition and attention in adults: pharmacological management strategies.	2007 Feb	19300541
Application of unsymmetrical indirect covariance NMR methods to the computation of the (13)C <--> (15)N HSQC-IMPEACH and (13)C <--> (15)N HMBC-IMPEACH correlation spectra.	2007 Oct	17729230
Mitigation of nociception via transganglionic degenerative atrophy: possible mechanism of vinpocetine-induced blockade of retrograde axoplasmic transport.	2008	18413267
Effects of Vinpocetine on mitochondrial function and neuroprotection in primary cortical neurons.	2008 Dec	18793690
Simultaneous determination of piracetam and vincamine by spectrophotometric and high-performance liquid chromatographic methods.	2008 Mar-Apr	18476342
Smart stability-indicating spectrophotometric methods for determination of binary mixtures without prior separation.	2008 Mar-Apr	18476341

Patents

Sample Use Guides

In Vivo Use Guide

Oxybral (Vincamine) Capsule contains 30 mg of vincamine in a sustained release pellet form. Oxybral (Vincamine) Ampoule for parenteral administration contains 15 mg of vincamine. Dosage in Adult: 1 capsule twice daily, 1 ampoule once or twice daily by IM or slow IV infusion

Route of Administration: Other

In Vitro Use Guide

Metabolic changes in alveolar macrophages and cell injury were evaluated in three studies carried out after 24 hr of gaseous phase culture in normoxia and in anaerobiosis with a possible treatment with 0.01 ug/ml vincamine: 1) ATP content assay by bioluminescence, the witness of cell vitality which decreases significantly in anaerobiosis; 2) Lactate assay which shows the metabolism derivation towards the anaerobic pathways; and 3) Tritiated deoxyglucose (DOG) incorporation, which shows glucose requirements after hypoxic incubation, maintaining or recovering a certain level of energetic activity.

Name

Type

Language

VINCAMINE HYDROCHLORIDE

Common Name

English

Vincamine hydrochloride [WHO-DD]

Common Name

English

ESBERIDIN

Brand Name

English

VINCAMINE HYDROCHLORIDE [MI]

Common Name

English

(3.ALPHA.,14.BETA.,16.ALPHA.)-14,15-DIHYDRO-14-HYDROXYEBURNAMENINE-14-CARBOXYLIC ACID METHYL ESTER HYDROCHLORIDE

Common Name

English

Code System Code Type Description

SMS_ID

100000087882